<DOC>
	<DOCNO>NCT02752412</DOCNO>
	<brief_summary>Primary Objective : To compare LixiLan insulin glargine glycated hemoglobin ( HbA1c ) change baseline week 26 patient type 2 diabetes mellitus . Secondary Objective : To compare overall efficacy safety LixiLan insulin glargine 26 week patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Safety LixiLan Versus Insulin Glargine Alone Both With Metformin Japanese With Type 2 Diabetes Mellitus Inadequately Controlled Basal Insulin Oral Antidiabetic Drugs</brief_title>
	<detailed_description>The maximum study duration per patient approximately 41 week : 14-week screening period ( consist 2-week screening phase 12-week run-in phase ) , 26-week randomized treatment period , 3-day post-treatment safety follow-up period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patient type 2 diabetes mellitus ( T2DM ) diagnose least 1 year screen visit ( V1 ) . Patient treat stable , day basal insulin regimen ( ie , type insulin time/frequency injection ) , least 3 month screen visit . The total daily basal insulin dose stable ( ± 20 % ) &lt; 15 U/day least 1 month screen visit . Patient receive 1 2 oral antidiabetic drug ( OADs ) : OAD dose ( ) must stable 3 month screen visit . The OADs 1 2 : Metformin ; Sulfonylurea ( SU ) ; Glinide ; Dipeptidylpeptidase4 ( DPP4 ) inhibitor ; Sodium glucose cotransporter 2 ( SGLT2 ) inhibitor ; Alpha glucosidase inhibitor ( alphaGI ) . Signed write informed consent . Exclusion criterion : Age &lt; 20 year screen visit . HbA1c screen visit &lt; 7.5 % &gt; 9.5 % . Fasting plasma glucose ( FPG ) &gt; 180 mg/dL ( 10.0 mmol/L ) screen visit . Pregnancy lactation , woman childbearing potential effective contraceptive method . Use oral injectable glucoselowering agent state inclusion criterion 3 month screen visit . Previous use insulin regimen basal insulin , eg , prandial premixed insulin . Note : Shortterm treatment ( ≤10 day ) due intercurrent illness include gestational diabetes allow discretion Investigator . Use thiazolidinedione ( TZD ) within 6 month prior screen visit . History discontinuation previous treatment glucagonlike peptide1 ( GLP1 ) receptor agonist due safety/ tolerability issue lack efficacy . Laboratory finding screen visit ; include : Amylase and/or lipase &gt; 3 time upper limit normal ( ULN ) laboratory range ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 ULN ; Calcitonin ≥20 pg/mL ( 5.9 pmol/L ) ; Positive serum pregnancy test . Any contraindication metformin use accord local labeling . History hypersensitivity GLP1 receptor agonist metacresol . Contraindication use insulin glargine lixisenatide accord local labeling . History hypersensitivity insulin glargine excipients . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC ( eg , multiple endocrine neoplasia syndrome ) . History pancreatitis ( unless pancreatitis relate gallstone cholecystectomy perform ) , pancreatitis previous treatment incretin therapy , chronic pancreatitis , pancreatectomy , stomach/gastric surgery . Exclusion criterion randomization end runin phase : HbA1c &lt; 7.5 % &gt; 9.5 % visit 6 ( Week 1 ) . Mean fast self monitor plasma glucose ( SMPG ) &gt; 160 mg/dL ( 8.9 mmol/L ) , calculate available ( minimum 4 selfmeasurements ) value 7 day prior randomization . Note : fasting SMPG day randomization include assessed randomization . Average insulin glargine daily dose ≥15 U/day &lt; 5U/day calculate last 3 day Visit 7 . Metformin total daily dose &lt; 750 mg/day . Amylase and/or lipase &gt; 3 ULN Visit 6 ( Week 1 ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>